Free Trial
NASDAQ:NCNA

NuCana (NCNA) Stock Price, News & Analysis

$3.52
0.00 (0.00%)
(As of 05/24/2024 ET)
Today's Range
$3.52
$3.75
50-Day Range
$3.50
$9.18
52-Week Range
$3.40
$23.75
Volume
9,584 shs
Average Volume
34,528 shs
Market Capitalization
$9.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$125.00

NuCana MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
3,451.1% Upside
$125.00 Price Target
Short Interest
Healthy
1.21% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.21mentions of NuCana in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($8.35) to ($10.52) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.89 out of 5 stars

NCNA stock logo

About NuCana Stock (NASDAQ:NCNA)

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells. Its pipeline includes NUC-3373, a chemical entity derived from the nucleoside analog 5-fluorouracil that is in Phase 1b/2 study in patients with metastatic colorectal cancer, Phase 2 clinical trial for the second-line treatment of patients with advanced colorectal cancer, and Phase 1b/2 modular clinical trial for patients with advanced solid tumors and lung cancer. It is also developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine, which is in the Phase 2 part of a Phase 1/2 clinical trial for patients with advanced solid tumors. The company has an assignment, license, and collaboration agreement with Cardiff ProTides Ltd to discover, drug design, and in vitro screen purine and pyrimidine-based nucleosides as potential drug candidates. The company was formerly known as NuCana BioMed Limited and changed its name to NuCana plc in August 2017. NuCana plc was incorporated in 1997 and is headquartered in Edinburgh, the United Kingdom.

NCNA Stock Price History

NCNA Stock News Headlines

NuCana plc (NCNA)
NuCana Announces Completion of ADS Ratio Change
NuCana Announces Plan to Implement ADS Ratio Change
Nucana (NCNA) Receives a Hold from TD Cowen
NuCana: Q4 Earnings Insights
Why NuCana Stock Is Up Today
Why Is NuCana (NCNA) Stock Up 102% Today?
See More Headlines
Receive NCNA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NuCana and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/20/2024
Today
5/26/2024
Next Earnings (Estimated)
8/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NCNA
Fax
N/A
Employees
25
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$125.00
High Stock Price Target
$150.00
Low Stock Price Target
$100.00
Potential Upside/Downside
+3,451.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-34,370,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.86 per share

Miscellaneous

Free Float
1,818,000
Market Cap
$9.29 million
Optionable
Not Optionable
Beta
1.03
The Best High-Yield Dividend Stocks for 2024 Cover

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. Hugh Stephen Griffith (Age 56)
    Founder, CEO & Executive Director
    Comp: $1.21M
  • Mr. Donald Munoz (Age 55)
    Chief Financial Officer
  • Mr. David Harrison (Age 64)
    Head of Translational Medicine
  • Dr. Jeffrey D. Bloss F.A.C.O.G. (Age 66)
    M.D., Chief Medical Officer
  • Ms. Theresa Bruce
    Senior Vice President of Clinical Operations
  • Ms. Elisabeth Oelmann
    Senior Vice President of Medical & Clinical Development
  • Martin Quinn
    Company Secretary

NCNA Stock Analysis - Frequently Asked Questions

Should I buy or sell NuCana stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for NuCana in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NCNA shares.
View NCNA analyst ratings
or view top-rated stocks.

What is NuCana's stock price target for 2024?

2 Wall Street research analysts have issued twelve-month target prices for NuCana's stock. Their NCNA share price targets range from $100.00 to $150.00. On average, they expect the company's stock price to reach $125.00 in the next twelve months. This suggests a possible upside of 3,451.1% from the stock's current price.
View analysts price targets for NCNA
or view top-rated stocks among Wall Street analysts.

How have NCNA shares performed in 2024?

NuCana's stock was trading at $7.3950 at the start of the year. Since then, NCNA stock has decreased by 52.4% and is now trading at $3.52.
View the best growth stocks for 2024 here
.

When is NuCana's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 21st 2024.
View our NCNA earnings forecast
.

How were NuCana's earnings last quarter?

NuCana plc (NASDAQ:NCNA) announced its earnings results on Wednesday, March, 20th. The company reported ($4.25) earnings per share for the quarter, missing analysts' consensus estimates of ($3.25) by $1.00.

When did NuCana's stock split?

NuCana's stock reverse split on Tuesday, April 16th 2024. The 1-25 reverse split was announced on Tuesday, April 16th 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, April 16th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

What other stocks do shareholders of NuCana own?
When did NuCana IPO?

NuCana (NCNA) raised $100 million in an initial public offering (IPO) on Thursday, September 28th 2017. The company issued 6,700,000 shares at $14.00-$16.00 per share. Citigroup, Jefferies and Cowen acted as the underwriters for the IPO and William Blair was co-manager.

How do I buy shares of NuCana?

Shares of NCNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NCNA) was last updated on 5/26/2024 by MarketBeat.com Staff

From Our Partners